184 related articles for article (PubMed ID: 17374732)
1. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line.
Komyod W; Böhm M; Metze D; Heinrich PC; Behrmann I
Mol Cancer Res; 2007 Mar; 5(3):271-81. PubMed ID: 17374732
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism.
Stross C; Radtke S; Clahsen T; Gerlach C; Volkmer-Engert R; Schaper F; Heinrich PC; Hermanns HM
J Biol Chem; 2006 Mar; 281(13):8458-68. PubMed ID: 16459330
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.
Pastuschek J; Poetzsch J; Morales-Prieto DM; Schleußner E; Markert UR; Georgiev G
J Reprod Immunol; 2015 Apr; 108():48-55. PubMed ID: 25817464
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
6. Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3.
Liu X; Liu R; Croker BA; Lawlor KE; Smyth GK; Wicks IP
Osteoarthritis Cartilage; 2015 Oct; 23(10):1743-54. PubMed ID: 26045176
[TBL] [Abstract][Full Text] [Related]
7. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α.
Tomita S; Ishibashi K; Hashimoto K; Sugino T; Yanagida T; Kushida N; Shishido K; Aikawa K; Sato Y; Suzutani T; Yamaguchi O
Cancer Sci; 2011 Jan; 102(1):57-63. PubMed ID: 21054677
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
9. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation.
Dimitriadis E; Stoikos C; Tan YL; Salamonsen LA
Endocrinology; 2006 Aug; 147(8):3809-17. PubMed ID: 16709613
[TBL] [Abstract][Full Text] [Related]
11. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
12. Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3.
Lan F; Zhang N; Zhang J; Krysko O; Zhang Q; Xian J; Derycke L; Qi Y; Li K; Liu S; Lin P; Bachert C
J Allergy Clin Immunol; 2013 Dec; 132(6):1314-21. PubMed ID: 23910692
[TBL] [Abstract][Full Text] [Related]
13. Regulation of suppressor of cytokine signaling 3 (SOC3) by growth hormone in pro-B cells.
Barclay JL; Anderson ST; Waters MJ; Curlewis JD
Mol Endocrinol; 2007 Oct; 21(10):2503-15. PubMed ID: 17609438
[TBL] [Abstract][Full Text] [Related]
14. Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells.
Lacreusette A; Barbieux I; Nguyen JM; Pandolfino MC; Dréno B; Jacques Y; Godard A; Blanchard F
J Pathol; 2009 Apr; 217(5):665-76. PubMed ID: 19097071
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts.
Hergovits S; Mais C; Haan C; Costa-Pereira AP; Hermanns HM
J Cell Mol Med; 2017 Nov; 21(11):3087-3099. PubMed ID: 28560754
[TBL] [Abstract][Full Text] [Related]
16. Methylation status of the SOCS3 gene in human malignant melanomas.
Tokita T; Maesawa C; Kimura T; Kotani K; Takahashi K; Akasaka T; Masuda T
Int J Oncol; 2007 Mar; 30(3):689-94. PubMed ID: 17273770
[TBL] [Abstract][Full Text] [Related]
17. Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis.
Liu X; Croker BA; Campbell IK; Gauci SJ; Alexander WS; Tonkin BA; Walsh NC; Linossi EM; Nicholson SE; Lawlor KE; Wicks IP
Arthritis Rheumatol; 2014 Sep; 66(9):2391-402. PubMed ID: 24839265
[TBL] [Abstract][Full Text] [Related]
18. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes.
Prêle CM; Keith-Magee AL; Yerkovich ST; Murcha M; Hart PH
Immunology; 2006 Sep; 119(1):8-17. PubMed ID: 16925527
[TBL] [Abstract][Full Text] [Related]
19. Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells.
Fojtova M; Boudny V; Kovarik A; Lauerova L; Adamkova L; Souckova K; Jarkovsky J; Kovarik J
Br J Cancer; 2007 Jul; 97(2):231-7. PubMed ID: 17579625
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of gp130 cytokine effects on corticotroph AtT-20 cells--redundancy or specificity of neuroimmunoendocrine modulators?
Auernhammer CJ; Kopp FB; Vlotides G; Dorn F; Isele NB; Spöttl G; Cengic N; Weber MM; Senaldi G; Engelhardt D
Neuroimmunomodulation; 2004; 11(4):224-32. PubMed ID: 15249728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
